Investment Rating - The investment rating for the company is "Outperform the Market" [1]. Core Views - The company has a strong management team and operates in a high-barrier industry with significant growth potential. It has launched over 120 products since its establishment and has achieved revenue exceeding 10 billion yuan. The domestic market for its products and services is projected to reach 29.8 to 38.7 billion yuan [3][4]. - The company is leveraging domestic advantages to expand internationally, with a focus on high-end product replacement and competitive pricing compared to international giants [4][5]. - The company is expected to see improvements in gross and net profit margins, with domestic net profit margins projected to reach 25-30% in the long term [4][5]. - The company has made significant progress in securing its supply chain by increasing the proportion of self-developed core components [4][5]. Summary by Sections 1. Industry Position and Management - The company is a leader in high-end medical imaging and radiation therapy products, with a complete product line comparable to international competitors like GE and Siemens [10][11]. - The management team has extensive experience from international imaging giants, enhancing the company's competitive edge [4][10]. 2. Market Potential - The domestic market for imaging and radiation therapy equipment is expected to grow significantly, with a replacement market potential of 79.9 billion yuan [4][9]. - The global medical imaging equipment market is projected to reach 63.4 billion USD by 2030, providing substantial opportunities for the company [4][9]. 3. Financial Performance - The company has shown robust growth, with a CAGR of nearly 41% in revenue from 2018 to 2023, and is expected to continue this trend with projected revenues of 12.84 billion yuan in 2024 [5][12]. - The company’s net profit is forecasted to reach 2.21 billion yuan in 2024, with EPS expected to be 2.68 yuan [5][12]. 4. Competitive Advantages - The company has a strong R&D focus, with 17% of revenue allocated to R&D in 2023, enabling it to innovate rapidly and maintain a competitive edge [18][20]. - The company has successfully increased its market share in China, with CT and MR products showing significant growth in market penetration [13][15]. 5. International Expansion - The company has been expanding its international presence, with overseas revenue increasing from 11.74% in 2022 to 14.70% in 2023, and is expected to continue this upward trend [17][18]. - The company has established a presence in over 65 countries, enhancing its global brand recognition and market share [17][18].

[Table_MainInfo]行业研究/旅游服务业 证券研究报告 | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

[Table_MainInfo] 公司研究/旅游服务业/旅游综合 证券研究报告 王府井（600859）公司跟踪报告 2024 年 09 月 19 日 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | |-------------------------------------------------|--------------------| | 股票数据 | | | 09 [ Table_StockInfo 月 19 日收盘价（元） ] | 12.10 | | 52 周股价波动（元） | 11.52-21.12 | | 总股本 / 流通 A 股（百万股） | 1135/1093 | | 总市值 / 流通市值（百万元） | 13734/13231 | | 相关研究 | | | [Table_ReportInfo] 《 3Q23 净利增 277% | ，奥莱维持高增长》 | | 2024.01.20 | | 市场表现 [Table_QuoteInfo] -43.51% -34.51% -25.51% -16.51% -7.51% 2023/9 2023/12 2024/ ...

[Table_MainInfo] 公司研究/信息服务/软件 证券研究报告 卫宁健康（300253）公司跟踪报告 2024 年 09 月 19 日 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | |-------------------------------------------------------------|------------| | 股票数据 | | | 09 [ Table_StockInfo 月 19 日收盘价（元） ] | 5.34 | | 52 周股价波动（元） | 5.11-8.38 | | 总股本 / 流通 A 股（百万股） | 2160/1862 | | 总市值 / 流通市值（百万元） | 11536/9941 | | 相关研究 | | | [Table_ReportInfo] 《利润表现亮眼，新签订单节奏有望加快》 | | | 2024.05.11 | | | 《" 1+X "战略，引领医疗健康信息行业》 | | | 2024.03.14 | | 市场表现 [Table_QuoteInfo] -31.97% -21.97% -11.9 ...

[Table_MainInfo]行业研究/信息设备/电子元器件 证券研究报告 [Table_AuthorInfo] [Table_InvestInfo] 投资评级 优于大市 维持 市场表现 [Table_QuoteInfo] 2995.45 4106.95 5218.45 6329.96 7441.46 8552.96 2023/9 2023/12 2024/3 2024/6 电子元器件 海通综指 资料来源：海通证券研究所 | --- | |--------------------------------------------------------------------------| | | | 相关研究 | | [Table_ReportInfo] 《光博会盛大开幕，关注 AR 光学创新》 2024.09.18 | | 《电子行业周报（ 2024/09/09-09/13 ）》 | | 2024.09.18 《半导体存储行业周报 240909-0913 》 | | 2024.09.15 | 分析师:张晓飞 Email:zxf15282@haitong.com 证书:S0850523030002 分析师: ...

[Table_MainInfo]行业研究/交通运输/航空公司 证券研究报告 行业跟踪报告 2024 年 09 月 19 日 [Table_AuthorInfo] 分析师:陈宇 [Table_InvestInfo] 投资评级 优于大市 维持 市场表现 | --- | --- | |----------------------------|------------------------------------| | | | | [Table_QuoteInfo] 航空公司 | 海通综指 | | | | | | | | | | | | | | 2024/3 | 2024/6 | | 资料来源：海通证券研究所 | | | | | | [Table_ReportInfo] | 月行业供需同比改善，客座率明显提 | | | 月行业供给环比收紧，客座率改善》 | | | 月行业供需环比回升，需求逐步修复》 | | --- | |---------------------------| | | | Tel:(021)23185610 | | Email:cy13115@haitong.com | | 证书 :S085052 ...

[Table_MainInfo]行业研究/食品 证券研究报告 行业专题报告 2024 年 09 月 19 日 [Table_AuthorInfo] [Table_InvestInfo] 投资评级 优于大市 维持 市场表现 [Table_QuoteInfo] 2995.45 7466.85 11938.25 16409.65 20881.05 25352.44 2023/9 2023/12 2024/3 2024/6 食品 海通综指 资料来源：海通证券研究所 相关研究 [Table_ReportInfo] 《8 月 CPI 当月同比+0.6%》2024.09.18 《7 月消费者信心指数同比-0.46%》 2024.09.11 《白酒韧性仍足分化加剧，啤酒需求承压 成本红利兑现》2024.09.08 分析师:颜慧菁 | --- | |----------------------------| | | | Email:yhj12866@haitong.com | | 证书 :S0850520020001 | | 分析师 : 程碧升 | | Tel:(021)23154171 | | Email:cbs10969@ ...

[Table_MainInfo]行业研究/金融/银行 证券研究报告 行业专题报告 2024 年 09 月 19 日 [Table_AuthorInfo] [Table_InvestInfo] 投资评级 优于大市 维持 市场表现 [Table_QuoteInfo] -11.99% -4.31% 3.36% 11.03% 18.71% 26.38% 2023/9 2023/12 2024/3 2024/6 银行 海通综指 资料来源：海通证券研究所 相关研究 [Table_ReportInfo] 《7 月社融数据点评：贷款降票据升，居 民长贷同比改善》2024.08.13 《周报：6 月新发放贷款利率环比下降， Q2 上市银行利润增速有望提升》 2024.08.13 《养老金融银行篇：向精、向全、向实》 2024.08.26 分析师:林加力 Tel:(021)23154395 Email:ljl12245@haitong.com 证书:S0850518120003 分析师:董栋梁 Tel:(021)23185697 Email:ddl13206@haitong.com 证书:S0850523100001 分析师:徐 ...

[Table_MainInfo]行业研究/机械工业/电气设备 证券研究报告 | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------- ...

[Table_MainInfo] 公司研究/信息服务/软件 证券研究报告 创业慧康（300451）公司跟踪报告 2024 年 09 月 19 日 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | |-----------------------------------------------------------------|-----------| | 股票数据 | | | 09 [ Table_StockInfo 月 18 日收盘价（元） ] | 3.23 | | 52 周股价波动（元） | 3.06-7.96 | | 总股本 / 流通 A 股（百万股） | 1549/1527 | | 总市值 / 流通市值（百万元） | 5004/4931 | | 相关研究 | | | [Table_ReportInfo] 《 Hi-HIS 推广新阶段，盈利能力有望快速修 | | | 复》 2024.04.15 | | 市场表现 [Table_QuoteInfo] -51.67% -36.67% -21.67% -6.67% 8.33% 2023/9 2023/12 2024/ ...